Clinical Report: Analyzing the Research Landscape of ICI-Induced Colitis

Overview

This bibliometric study analyzes 1,010 publications on immune checkpoint inhibitor (ICI)-induced colitis, highlighting the United States as the leading contributor. Key research themes include the need for improved management strategies and the exploration of combination therapies.

Background

Immune checkpoint inhibitors have revolutionized cancer treatment but are associated with immune-related adverse events (irAEs), particularly colitis. Understanding the research landscape surrounding ICI-induced colitis is crucial for developing effective management strategies and improving patient outcomes. This study provides insights into current trends and future directions in this emerging field.

Data Highlights

Key Findings

• The United States leads in both publication volume and total citations in ICI-induced colitis research.
• The University of Texas MD Anderson Cancer Center is the top institution for publications in this field.
• Wang Yinghong is identified as the most prolific author in the literature.
• Research keywords indicate a focus on Ipilimumab, Nivolumab, and Pembrolizumab, among others.
• Future research should focus on combination therapies and the identification of biomarkers for adverse events.

Clinical Implications

Clinicians should be aware of the increasing incidence of ICI-induced colitis and the need for effective management strategies. The findings emphasize the importance of ongoing research into combination therapies and biomarkers to enhance patient care and safety in immunotherapy.

Conclusion

This bibliometric analysis underscores the growing body of research on ICI-induced colitis and highlights critical areas for future investigation. Continued exploration of management strategies and underlying mechanisms is essential for improving patient outcomes.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- Global research trends and hotspots of colorectal cancer organoids: a bibliometric insight and visualization analysis via multiple databases
2. Clinical Rheumatology, 2025 -- A bibliometric review of immunotherapy approaches for systemic lupus erythematosus: an evaluation of literature from 2014 to 2024
3. Frontiers in Immunology, 2026 -- Research trends on autoimmune liver diseases and gut microbiota (1989–2025): a bibliometric and visualization analysis based on the web of science core collection database
4. British Journal of Cancer, 2024 -- Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review
5. the new gastroenterologist — New Crohn's data spotlight promising therapies
6. New Crohn's data spotlight promising therapies
7. Infliximab for immune checkpoint inhibitor therapy-related toxicities
8. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review | British Journal of Cancer
9. Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals